drug

DYNE-251

1 story · latest Jul 22, 2026

Status: Investigational
Trials: 1 registered trial in coverage

Relationships

Developed by Dyne Therapeutics

Timeline

Dyne Therapeutics prices upsized $375 million stock offering at $20.50 a share

Jul 22FinancingDyne Therapeutics

Biotech intelligence from primary sources. Every story is an original summary of a public record, linked to its source. Not investment advice.

Terms Privacy hello@readthrough.news

readthrough is a product of JAMN Ventures, LLC.